About cue biopharma inc - CUE
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.
CUE At a Glance
Cue Biopharma, Inc.
40 Guest Street
Boston, Massachusetts 02135
| Phone | 1-617-949-2680 | Revenue | 27.47M | |
| Industry | Biotechnology | Net Income | -26,602,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 195.747% | |
| Fiscal Year-end | 12 / 2026 | Employees | 29 | |
| View SEC Filings |
CUE Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.053 |
| Price to Book Ratio | 1.116 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.229 |
| Enterprise Value to Sales | 0.218 |
| Total Debt to Enterprise Value | 0.70 |
CUE Efficiency
| Revenue/Employee | 947,103.448 |
| Income Per Employee | -917,310.345 |
| Receivables Turnover | 3.689 |
| Total Asset Turnover | 0.729 |
CUE Liquidity
| Current Ratio | 2.741 |
| Quick Ratio | 2.741 |
| Cash Ratio | 2.011 |
CUE Profitability
| Gross Margin | 98.734 |
| Operating Margin | -96.559 |
| Pretax Margin | -95.034 |
| Net Margin | -96.854 |
| Return on Assets | -70.622 |
| Return on Equity | -121.108 |
| Return on Total Capital | -86.852 |
| Return on Invested Capital | -112.673 |
CUE Capital Structure
| Total Debt to Total Equity | 15.878 |
| Total Debt to Total Capital | 13.703 |
| Total Debt to Total Assets | 9.728 |
| Long-Term Debt to Equity | 8.649 |
| Long-Term Debt to Total Capital | 7.464 |